EyeGene Inc
EyeGene Inc. engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. Its product pipeline comprises EG-Mirotin, which has completed Phase 2a clinical trial to treat diabetic retinopathy; EG-Decorin which completed Phase 2 clinical trial for the treatment of pressure ulcers and wound healing; and EG-Myocin, which h… Read more
EyeGene Inc (185490) - Net Assets
Latest net assets as of September 2025: ₩44.06 Billion KRW
Based on the latest financial reports, EyeGene Inc (185490) has net assets worth ₩44.06 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩56.60 Billion) and total liabilities (₩12.55 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩44.06 Billion |
| % of Total Assets | 77.83% |
| Annual Growth Rate | 29.29% |
| 5-Year Change | 290.11% |
| 10-Year Change | 121.07% |
| Growth Volatility | 222.48 |
EyeGene Inc - Net Assets Trend (2014–2024)
This chart illustrates how EyeGene Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for EyeGene Inc (2014–2024)
The table below shows the annual net assets of EyeGene Inc from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩50.32 Billion | -21.78% |
| 2023-12-31 | ₩64.33 Billion | -3.59% |
| 2022-12-31 | ₩66.73 Billion | -25.00% |
| 2021-12-31 | ₩88.97 Billion | +589.72% |
| 2020-12-31 | ₩12.90 Billion | -32.22% |
| 2019-12-31 | ₩19.03 Billion | -18.48% |
| 2018-12-31 | ₩23.34 Billion | -1.72% |
| 2017-12-31 | ₩23.75 Billion | +46.76% |
| 2016-12-31 | ₩16.19 Billion | -28.90% |
| 2015-12-31 | ₩22.76 Billion | +490.68% |
| 2014-12-31 | ₩3.85 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to EyeGene Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 14494927944000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩13.51 Billion | 26.86% |
| Other Components | ₩198.55 Billion | 394.56% |
| Total Equity | ₩50.32 Billion | 100.00% |
EyeGene Inc Competitors by Market Cap
The table below lists competitors of EyeGene Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Garden Stage Limited Ordinary Shares
NASDAQ:GSIW
|
$19.45 Million |
|
Latvian Forest Company AB (publ)
F:2FD
|
$19.45 Million |
|
Hun Yenilenebilir Enerji Uretim AS
IS:HUNER
|
$19.46 Million |
|
Borlease Otomotiv A.S.
IS:BORLS
|
$19.46 Million |
|
Pusan Cast Iron Co., Ltd.
KO:005030
|
$19.44 Million |
|
TINYBUILD REGSCAT3 DL-001
F:8Z3
|
$19.43 Million |
|
WIN HANVERKY
MU:N2R
|
$19.43 Million |
|
CyberCatch Holdings Inc.
V:CYBE
|
$19.43 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in EyeGene Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 63,230,279,500 to 50,321,061,750, a change of -12,909,217,750 (-20.4%).
- Net loss of 12,128,140,660 reduced equity.
- New share issuances of 808,873,790 increased equity.
- Other factors decreased equity by 1,589,950,880.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-12.13 Billion | -24.1% |
| Share Issuances | ₩808.87 Million | +1.61% |
| Other Changes | ₩-1.59 Billion | -3.16% |
| Total Change | ₩- | -20.42% |
Book Value vs Market Value Analysis
This analysis compares EyeGene Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.79x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.19x to 0.79x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩1231.29 | ₩1469.00 | x |
| 2017-12-31 | ₩1653.90 | ₩1469.00 | x |
| 2018-12-31 | ₩1621.25 | ₩1469.00 | x |
| 2019-12-31 | ₩1264.79 | ₩1469.00 | x |
| 2020-12-31 | ₩845.51 | ₩1469.00 | x |
| 2021-12-31 | ₩4155.60 | ₩1469.00 | x |
| 2022-12-31 | ₩3106.77 | ₩1469.00 | x |
| 2023-12-31 | ₩2339.28 | ₩1469.00 | x |
| 2024-12-31 | ₩1861.69 | ₩1469.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently EyeGene Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -24.10%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -361.41%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 1.30x
- Recent ROE (-24.10%) is above the historical average (-45.98%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -75.92% | -1902.44% | 0.03x | 1.44x | ₩-3.31 Billion |
| 2015 | -21.51% | -4552.80% | 0.00x | 1.07x | ₩-7.17 Billion |
| 2016 | -51.10% | -3094.59% | 0.01x | 1.15x | ₩-9.89 Billion |
| 2017 | -35.58% | -2807.29% | 0.01x | 1.27x | ₩-10.83 Billion |
| 2018 | -25.31% | -290.27% | 0.04x | 2.32x | ₩-8.24 Billion |
| 2019 | -45.93% | -205.88% | 0.09x | 2.49x | ₩-10.64 Billion |
| 2020 | -115.22% | -441.90% | 0.08x | 3.44x | ₩-16.15 Billion |
| 2021 | -38.85% | -1066.25% | 0.03x | 1.18x | ₩-43.47 Billion |
| 2022 | -38.89% | -490.29% | 0.07x | 1.20x | ₩-32.63 Billion |
| 2023 | -33.38% | -675.30% | 0.04x | 1.24x | ₩-27.43 Billion |
| 2024 | -24.10% | -361.41% | 0.05x | 1.30x | ₩-17.16 Billion |
Industry Comparison
This section compares EyeGene Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| EyeGene Inc (185490) | ₩44.06 Billion | -75.92% | 0.28x | $19.44 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |